Mutational Characterization of the Bile Acid Receptor TGR5 in Primary Sclerosing Cholangitis


Published in:
PLoS One

DOI:
10.1371/journal.pone.0012403

Link to publication

Citation for published version (APA):

General rights
It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).

Disclaimer/Complaints regulations
If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: http://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.

UvA-DARE is a service provided by the library of the University of Amsterdam (http://dare.uva.nl)

Download date: 23 Oct 2018
Mutational Characterization of the Bile Acid Receptor TGR5 in Primary Sclerosing Cholangitis

Johannes R. Hov1,2,3*, Verena Keitel4, Jon K. Laerdahl5, Lina Spomer4, Eva Ellinghaus6, Abdou ElSharawy6,7, Espen Melum1,2,3, Kirsten M. Boberg1, Thomas Manke8, Tobias Balschun6, Christoph Schramm9, Annika Bergquist10, Tobias Weismüller9,12, Daniel Gotthardt13, Christian Rust14, Liesbet Henckaerts15, Clive M. Onnie16, Rinse K. Weersma17, Martina Sternek9, Andreas Teufel18, Heiko Runz19, Adolf Stiehl13, Cyriel P. Vonsioen20, Csisa Wijmenga21, Morten H. Vatn3,22,23, for the IBSEN study group', Pieter C. F. Stokkers20, Severine Vermeire15, Christopher G. Mathew16, Benedicte A. Lie24, Ulrich Beuers20, Michael P. Manns11,12, Stefan Schreiber6,7, Erik Schrumpf1,3, Dieter Häussinger4, Andre Franke6, Tom H. Karlsen1

1 Norwegian PSC Research Center, Clinic for Specialized Medicine and Surgery, Oslo University Hospital Rikshospitalet, Oslo, Norway, 2 Research Institute for Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway, 3 Institute of Clinical Medicine, University of Oslo, Oslo, Norway, 4 Clinic for Gastroenterology, Hepatology and Infectiology, Heinrich-Heine-University, Düsseldorf, Germany, 5 Centre for Molecular Biology and Neuroscience and Institute of Medical Microbiology, Oslo University Hospital Rikshospitalet, Oslo, Norway, 6 Institute of Clinical Molecular Biology, Christian-Albrechts University, Kiel, Germany, 7 First Department of Medicine, University Hospital Schleswig-Holstein, Kiel, Germany, 8 Max Planck Institute for Molecular Genetics, Berlin, Germany, 9 1st Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, 10 Department of Gastroenterology and Hepatology, Karolinska University Hospital Huddinge, Stockholm, Sweden, 11 Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany, 12 Integrated Research and Treatment Center - Transplantation (IFB-Tx), Hannover Medical School, Hannover, Germany, 13 Department of Medicine, University Hospital of Heidelberg, Heidelberg, Germany, 14 Department of Medicine II, Grosshadern, University of Munich, Munich, Germany, 15 Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium, 16 Department of Medical and Molecular Genetics, King’s College London School of Medicine, London, United Kingdom, 17 Department of Gastroenterology and Hepatology, University Medical Center Groningen and University of Groningen, Groningen, The Netherlands, 18 1st Department of Medicine, University of Mainz, Mainz, Germany, 19 Department of Human Genetics, University Hospital of Heidelberg, Heidelberg, Germany, 20 Department of Gastroenterology and Hepatology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands, 21 Department of Genetics, University Medical Center Groningen and University of Groningen, Groningen, The Netherlands, 22 Institute of Clinical Epidemiology and Molecular Biology (Epigen), Akershus University Hospital, Lørenskog, Norway, 23 Clinic for Specialized Medicine and Surgery, Oslo University Hospital Rikshospitalet, Oslo, Norway, 24 Institute of Immunology, Oslo University Hospital Rikshospitalet, Oslo, Norway

Abstract

Background: TGR5, the G protein-coupled bile acid receptor 1 (GPBAR1), has been linked to inflammatory pathways as well as bile homeostasis, and could therefore be involved in primary sclerosing cholangitis (PSC) a chronic inflammatory bile duct disease. We aimed to extensively investigate TGR5 sequence variation in PSC, as well as functionally characterize detected variants.

Methodology/Principal Findings: Complete resequencing of TGR5 was performed in 267 PSC patients and 274 healthy controls. Six nonsynonymous mutations were identified in addition to 16 other novel single-nucleotide polymorphisms. To investigate the impact from the nonsynonymous variants on TGR5, we created a receptor model, and introduced mutated TGR5 constructs into human epithelial cell lines. By using confocal microscopy, flow cytometry and a cAMP-sensitive luciferase assay, five of the nonsynonymous mutations (W83R, V178M, A217P, S272G and Q296X) were found to reduce or abolish TGR5 function. Fine-mapping of the previously reported PSC and UC associated locus at chromosome 2q35 in large patient panels revealed an overall association between the TGR5 single-nucleotide polymorphism rs11554825 and PSC (odds ratio = 1.14, 95% confidence interval: 1.03–1.26, p = 0.010) and UC (odds ratio = 1.19, 95% confidence interval 1.11–1.27, p = 8.5 × 10−5), but strong linkage disequilibrium precluded demarcation of TGR5 from neighboring genes.

Conclusions/Significance: Resequencing of TGR5 along with functional investigations of novel variants provided unique insight into an important candidate gene for several inflammatory and metabolic conditions. While significant TGR5 associations were detected in both UC and PSC, further studies need to be conducted to conclusively define the role of TGR5 variation in these diseases.


Editor: Pieter H. Reitsma, Leiden University Medical Center, The Netherlands

Received April 18, 2010; Accepted July 14, 2010; Published August 25, 2010

Copyright: © 2010 Hov et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This study was supported by the Norwegian PSC research center, Research Council of Norway, the Deutsche Forschungsgemeinschaft through Sonderforschungsbereich 575 Düsseldorf “Experimental Hepatology” and Klinische Forschergruppe-217 Düsseldorf “Hepatobiliary transport and liver disease” and the German Ministry of Education and Research (BMBF) through the National Genome Research Network (NGFN), the Pogen biobank, the DFG excellence cluster “Inflammation at Interfaces” and the Integrated Research and Treatment Center - Transplantation (reference number: 01E0802). The 1958 British Birth Cohort collection is funded by the United Kingdom Medical Research Council (MRC, grant G0000934) and The Wellcome Trust (grant 068545/Z/02). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Introduction

TGR5, the G protein-coupled bile acid receptor 1 (GPBAR1), was recently identified as the first plasma membrane-bound bile acid receptor [1,2]. TGR5 is strongly expressed in monocytes and macrophages, and the receptor has been shown to inhibit the release of inflammatory cytokines from activated macrophages [2,3]. A role in bile homeostasis and metabolic regulation is suggested by TGR5 knockout mice, which are resistant to gallstones and obesity [4–7]. In the hepatobiliary system, TGR5 protein expression has been demonstrated in rodent Kupffer cells, liver sinusoidal endothelium and biliary epithelium [3,8]. Investigations in humans have so far been limited to the gallbladder, where TGR5 is co-localized with the cystic fibrosis transmembrane conductance regulator (CFTR) [9]. Stimulation of TGR5 in gallbladder cells activates CFTR [9], suggesting that the secretory functions of cholangiocytes may be regulated by this interaction.

Given the bile acid specificity and involvement in inflammatory pathways, TGR5 is a plausible candidate for involvement in hepatobiliary diseases. Primary sclerosing cholangitis (PSC) is a chronic inflammatory condition of the intra- and extrahepatic bile ducts with a prevalence of approximately 10 per 100,000 in Western countries [10,11]. PSC is strongly linked to inflammatory bowel disease, which affects up to 80% of the patients [12], most often classified as ulcerative colitis (UC), a chronic inflammatory disease of the colonic mucosa [13]. The etiology of PSC and the link to intestinal inflammation is poorly understood [14], but a role of genetic factors in the pathogenesis is likely [15]. TGR5 function has so far not been investigated in PSC, but given the interaction with CFTR, it is interesting that cystic fibrosis (caused by CFTR mutations) may involve liver disease, often resembling PSC [16]. Intriguingly, induction of colitis in Cb1r knockout mice leads to bile duct injury [17], and reduced CFTR function has been reported in PSC patients [18,19], even in the absence of CFTR mutations [19]. Thus, intestinal inflammation seems to increase vulnerability to biliary injury when CFTR function is impaired, and TGR5 could be speculated to be involved.

Little is known about the details of TGR5 structure and how mutations affect function. Whether sequence variation may confer disease susceptibility is also not known. However, the gene is located on chromosome 2q35, close to the single-nucleotide polymorphism (SNP) rs12612347 that we recently found associated with both UC [replication OR = 1.18 (1.08–1.28) p = 2.0 × 10^{-4}] and PSC [in a study assessing UC findings in PSC, OR = 1.26 (1.06–1.50), p = 0.0088] in genome-wide association studies [20,21]. Further investigation of this locus has so far not been performed. Given the potential role of TGR5 in bile homeostasis and inflammation, we aimed to make a detailed genetic and functional characterization of TGR5 in PSC, and in parallel assess its possible association with UC and UC.

Materials and Methods

Ethics Statement

This study was approved by the Regional Committee for Medical Research Ethics, South-Eastern Norway, in addition to approval from the ethics committees at all involved centers. Written informed consent was obtained from all participants.

Subjects

A total of 267 Norwegian PSC patients and 274 healthy controls were included for sequencing of TGR5 (Table 1). The PSC patients were recruited on admission to Oslo University Hospital Rikshospitalet, while healthy controls were randomly selected from the Norwegian Bone Marrow Donor Registry (NORDONOR). The diagnosis of PSC was based on standard clinical, biochemical, histological and cholangiographic criteria [22]. The diagnosis of inflammatory bowel disease was based on clinical, radiological, histological, and endoscopic (i.e. type and distribution of lesions) criteria [23].

A total of 1109 PSC patients (69% male, 73% with concomitant inflammatory bowel disease), 2761 UC patients (47% male) and 4697 healthy controls were available for genotyping (including the sequenced individuals). These came from Norway and Sweden (panel 1), Belgium and the Netherlands (panel 2), Germany (panel 3) and the United Kingdom (panel 4). Details are described in Materials and Methods S1, including the extent of overlap between the patient panels in the present study and those used in the previous genome-wide association studies. For fine-mapping, a total of 285 Norwegian PSC patients, 892 German and British patients with UC and 2496 healthy controls (subsets of panel 1, 3 and 4) were genotyped.

TGR5 Resequencing

In order to include all TGR5 transcript variants so far reported, the entire TGR5 and 1,509 basepairs of the 5’ region were covered by nine primer pairs (Figure 1 and Table S1). For amplification, a standard touchdown PCR was applied using Taq Gold (Applied Biosystems). A 25 μL reaction contained 2.5 μL ×10 buffer, 3 μL MgCl₂, 0.5 μL dNTPs (10 mM), 0.4 μL forward primer (10 mM), 0.4 μL reverse primer (10 mM), 0.15 μL taq, 13.05 μL water and 5 μL DNA input (1 ng/μL). The PCR program was as follows: 95°C for 12 min, 95°C for 30 sec, 72°C for 30 sec×16 cycles [td –0.5°C], 95°C for 30 sec, Tm –8°C for 30 sec, 72°C for 30 sec×19 cycles, 72°C for 10 min, 10°C for ñ. Sequencing was performed using BigDye™ chemistry (Applied Biosystems) according to standard manufacturer’s instructions. All sequences were inspected for SNPs, insertions and deletions in both SeqScape v2.5 (Applied Biosystems) and novoSNP v3.0 [24]. All assigned SNPs were observed in both forward and reverse sequences.

Genotyping

Based on significant associations in UC and PSC genome-wide association studies [20,21], a 238 kilobasepairs large genetic region was selected for fine-mapping. A HapMap tagging approach was combined with the addition of associated SNPs from the UC study [20] and hand-picked non-HapMap SNPs. A total of 45 SNPs passed assay design and were genotyped using ligation-based SNPlex® genotyping (Applied Biosystems, Foster City, CA, USA) as described elsewhere [25–27]. Rs11554825 was genotyped using a TaqMan® assay (Applied Biosystems). Only SNPs with minor allele frequencies >0.01, genotyping success rate >0.95 and no significant deviation from Hardy-Weinberg equilibrium in the healthy controls (P>0.01) were included for association analysis.
Table 1. Characteristics of resequenced individuals.

<table>
<thead>
<tr>
<th></th>
<th>PSC (n = 267)</th>
<th>Healthy controls (n = 274)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at diagnosis, median (range)</td>
<td>33 (12–73)</td>
<td>32* (18–46)</td>
</tr>
<tr>
<td>Male sex, n (%)</td>
<td>196 (73)</td>
<td>157 (57)</td>
</tr>
<tr>
<td>Inflammatory bowel disease, n (%)</td>
<td>214 (80)</td>
<td>-</td>
</tr>
<tr>
<td>Cholangiocarcinoma, n (%)</td>
<td>27 (10)</td>
<td>-</td>
</tr>
<tr>
<td>Liver transplanted or deceased, n (%)</td>
<td>130 (49)</td>
<td>-</td>
</tr>
<tr>
<td>Transplantation as primary endpoint, n (%)</td>
<td>87 (33)</td>
<td>-</td>
</tr>
<tr>
<td>Observation time to transplantation or death (years), median (range)</td>
<td>8 (0–32)</td>
<td>-</td>
</tr>
</tbody>
</table>

*Age at sampling.

TGR5 Structural Modeling and Sequence Data Collection

Publicly available database resources provided by the Ensembl project (http://www.ensembl.org), the DOE Joint Genome Institute (http://genome.jgi-psf.org), the UniProt Consortium (http://www.uniprot.org), and the NCBI (http://www.ncbi.nlm.nih.gov) were searched for homologs of human TGR5. Multiple sequence alignments (MSAs) were generated with Muscle [28], TCOffee [29], MCoffee [30], and Expresso [31], and the MSAs were viewed and manipulated in Jalview [32]. Structural disorder predictions were generated with DISOPRED2 (http://bioinf.cs.ucl.ac.uk/disopred) [33]. A model for the structurally ordered segments of TGR5 was generated from a template 3EML from the Protein Data Bank (http://www.pdb.org) employing standard homology modeling with SwissModel [34]. 3EML is the experimental structure of human adenosine A2a receptor from Jaikola et al. [35].

Cloning and Mutagenesis of Human TGR5

Human TGR5 was cloned from liver cDNA as previously described [9] (details in Materials and Methods S1). Three different plasmids were generated: 1) TGR5 only, containing the entire coding sequence including the stop codon (pcDNA3.1 vector, Invitrogen, Karlsruhe, Germany), 2) TGR5-yellow fluorescent protein (TGR5-YFP), containing the coding sequence with a C-terminal YFP-tag (pEYFP-N1 vector, Clontech, Palo Alto, CA, USA), and 3) FLAG-TGR5-YFP, containing the coding sequence with an N-terminal FLAG-tag and a C-terminal YFP-tag (pEYFP-N1). Mutations were introduced using the Multisite-mutagenesis kit (Stratagene, La Jolla, CA, USA). Successful cloning and mutagenesis was verified by sequencing.

Immunofluorescence Staining

HEK293 (CRL-1573) and MDCK (CCL-34) cell lines were obtained from American Type Culture Collection (Manassas, VA, USA). Both HEK293 (grown on glass coverslips) and MDCK (grown on filterwells) cells were transiently transfected with TGR5 constructs using LipofectAMINE-2000 (Invitrogen). After 48 h cells were fixed in 100% methanol (−20°C, 5 min), immunostained and analyzed on a Zeiss LSM510META confocal microscope using a multitracking modus. A 63x objective and a scanning resolution of 1024×1024 pixels was used for all samples. The following antibodies were used: M39 (TGR5) 1:500, Na+/K+ ATPase (Sigma, Taufkirchen, Germany) 1:100, anti-FLAG-M2 (Sigma) 1:250. Fluorescein and Cyanine-3 conjugated secondary antibodies (Dianova, Hamburg, Germany) were diluted 1:100 and 1:500, respectively. Nuclei were stained with Hoechst (1:20.000; Invitrogen).

Flow Cytometry

In order to quantify protein expression and plasma membrane localization, flow cytometry was performed. HEK293 cells were transiently transfected with the TGR5-YFP or FLAG-TGR5-YFP constructs. After 48 h cells were washed with ice-cold phosphate-buffered saline (PBS), detached by pipetting with 1 ml PBS, centrifuged (2,000 g for 3 min at 4°C), resuspended in PBS, and washed twice by centrifugation and resuspension. For measure...
ment of transfection efficacy and protein expression, cell size (forward scatter), granularity (sideward scatter), and fluorescence were analyzed in 50,000 cells using a FACSACTO-II (BD Biosciences, Heidelberg, Germany). Cells with YFP-fluorescence greater than $10^3$ were gated and denoted as TGR5-YFP-transfected cells. TGR5 protein expression was measured as mean fluorescence intensity per transfected cell (using the BD FACSDiva Software), normalized to wild-type.

Plasma membrane expression was quantified by determining the amount of the FLAG-tag on the extracellular surface and normalizing to the total amount of TGR5 (determined by YFP-fluorescence): Anti-FLAG M2 was labeled with PacificBlue conjugated anti-mouse IgG-Fab-fragments using the Zenon PacificBlue Label-Kit (Invitrogen). Cells were incubated 30 min ($4^\circ$C) with the labeled antibody (1:250). Afterwards cells were washed twice with ice cold PBS and measured for forward scatter, sideward scatter, YFP- and PacificBlue-fluorescence. The following controls were used: Unlabeled non-transfected cells (no fluorescence); unlabeled FLAG-TGR5-YFP transfected cells (only YFP-fluorescence), labeled FLAG-TGR5-Q296X transfected cells (only PacificBlue-fluorescence). The amount of TGR5 in the plasma membrane was determined as the amount of PacificBlue-YFP-positive cells divided by the total amount of YFP-positive cells. As control, detection of every YFP-positive cell with the anti-FLAG antibody in permeabilized cells was performed: Detached cells were fixed in 4% paraformaldehyde (15 min at room temperature), washed with PBS and permeabilized using 0.1% Triton-X (5 min). Afterwards cells were washed twice, incubated with the labeled anti-FLAG-M2 antibody, washed again and analyzed.

**Measurement of cAMP**

Receptor activity was investigated using the TGR5 agonist taurolithocholic acid (TLC) [36]. HEK293 cells were cotransfected with TGR5, followed by transfection with an empty vector or one of the other plasmids, and analyzed for cAMP production. cAMP levels were measured using an enzyme-linked immunosorbent assay (ELISA) (Assay Designs, Ann Arbor, MI).

**Table 2.** Single-nucleotide polymorphisms (SNPs) detected at the TGR5 locus by complete resequencing of the gene (exons, introns, and untranslated regions) in 267 Norwegian PSC patients and 274 healthy controls.

<table>
<thead>
<tr>
<th>dbSNP ID/name</th>
<th>Chromosome 2 position</th>
<th>Alleles</th>
<th>Category</th>
<th>Minor allele count (frequency)</th>
</tr>
</thead>
<tbody>
<tr>
<td>rs3731859</td>
<td>218,832,467</td>
<td>A/G</td>
<td>5’UTR</td>
<td>245 (0.46) 223 (0.41)</td>
</tr>
<tr>
<td>TGR5snp1</td>
<td>218,832,492</td>
<td>C/T</td>
<td>5’UTR</td>
<td>2 1</td>
</tr>
<tr>
<td>TGR5snp2</td>
<td>218,832,779</td>
<td>C/T</td>
<td>5’UTR</td>
<td>1 1</td>
</tr>
<tr>
<td>rs13003334</td>
<td>218,833,166</td>
<td>A/T</td>
<td>5’UTR</td>
<td>241 (0.45) 222 (0.41)</td>
</tr>
<tr>
<td>TGR5snp3</td>
<td>218,833,670</td>
<td>A/G</td>
<td>5’UTR</td>
<td>0 1</td>
</tr>
<tr>
<td>rs11554825</td>
<td>218,834,054</td>
<td>T/C</td>
<td>Exon 1 untranslated</td>
<td>246 (0.46) 225 (0.41)</td>
</tr>
<tr>
<td>TGR5snp4</td>
<td>218,834,358</td>
<td>G/T</td>
<td>Intron</td>
<td>1 0</td>
</tr>
<tr>
<td>TGR5snp5</td>
<td>218,834,372</td>
<td>G/A</td>
<td>Intron</td>
<td>1 9</td>
</tr>
<tr>
<td>TGR5snp6</td>
<td>218,834,433</td>
<td>G/T</td>
<td>Intron</td>
<td>11 (0.02) 12 (0.02)</td>
</tr>
<tr>
<td>TGR5snp7</td>
<td>218,834,814</td>
<td>A/T</td>
<td>Intron</td>
<td>0 1</td>
</tr>
<tr>
<td>rs1567869</td>
<td>218,834,980</td>
<td>T/C</td>
<td>Intron</td>
<td>12 (0.02) 12 (0.02)</td>
</tr>
<tr>
<td>TGR5snp8</td>
<td>218,835,162</td>
<td>G/C</td>
<td>Exon2 untranslated</td>
<td>1 1</td>
</tr>
<tr>
<td>TGR5snp9</td>
<td>218,835,335</td>
<td>C/T</td>
<td>Exon2 untranslated</td>
<td>0 1</td>
</tr>
<tr>
<td>TGR5snp10</td>
<td>218,835,416</td>
<td>G/A</td>
<td>Exon2 untranslated</td>
<td>0 1</td>
</tr>
<tr>
<td>TGR5snp11</td>
<td>218,835,569</td>
<td>G/A</td>
<td>Exon2 untranslated</td>
<td>0 1</td>
</tr>
<tr>
<td>rs7621524</td>
<td>218,835,654</td>
<td>C/T</td>
<td>Exon 2 untranslated</td>
<td>1 0</td>
</tr>
<tr>
<td>rs5192869</td>
<td>218,835,662</td>
<td>G/A</td>
<td>Exon 2 untranslated</td>
<td>1 0</td>
</tr>
<tr>
<td>TGR5snp12</td>
<td>218,835,744</td>
<td>T/C</td>
<td>Exon 2 synonymous</td>
<td>0 1</td>
</tr>
<tr>
<td>TGR5snp21</td>
<td>218,835,938</td>
<td>T/C</td>
<td>W83R</td>
<td>1 0</td>
</tr>
<tr>
<td>TGR5snp22</td>
<td>218,836,149</td>
<td>C/T</td>
<td>A153V</td>
<td>1 0</td>
</tr>
<tr>
<td>TGR5snp13</td>
<td>218,836,223</td>
<td>G/A</td>
<td>V178M</td>
<td>1 0</td>
</tr>
<tr>
<td>TGR5snp14</td>
<td>218,836,327</td>
<td>C/T</td>
<td>Exon 2 synonymous</td>
<td>5 4</td>
</tr>
<tr>
<td>TGR5snp15</td>
<td>218,836,339</td>
<td>G/C</td>
<td>Exon 2 synonymous</td>
<td>11 (0.02) 12 (0.02)</td>
</tr>
<tr>
<td>TGR5snp16</td>
<td>218,836,340</td>
<td>G/C</td>
<td>A217P</td>
<td>1 3</td>
</tr>
<tr>
<td>TGR5snp17</td>
<td>218,836,505</td>
<td>A/G</td>
<td>S272G</td>
<td>1 0</td>
</tr>
<tr>
<td>TGR5snp18</td>
<td>218,836,577</td>
<td>C/T</td>
<td>Q296X</td>
<td>0 1</td>
</tr>
<tr>
<td>TGR5snp19</td>
<td>218,836,740</td>
<td>C/G</td>
<td>Exon 2 untranslated</td>
<td>3 2</td>
</tr>
<tr>
<td>rs2292549</td>
<td>218,836,750</td>
<td>T/C</td>
<td>Exon 2 untranslated</td>
<td>12 (0.02) 12 (0.02)</td>
</tr>
<tr>
<td>TGR5snp20</td>
<td>218,836,759</td>
<td>C/T</td>
<td>Exon 2 untranslated</td>
<td>11 (0.02) 12 (0.02)</td>
</tr>
</tbody>
</table>

*NCBI build 36.

1Resides in exon 2 as depicted in Figure 1, but shorter variants of exon 2 (which do not include the affected nucleotide) have been reported. Alleles = major/minor allele defined from positive strand. 5’UTR = 5’ untranslated region.

doi:10.1371/journal.pone.0012403.t002
fected with a cAMP-sensitive reporter gene construct (Bayer AG, Leverkusen, Germany) and TGR5 variants in pcDNA, using LipofectAMINE as described [8]. Control experiments were performed with the empty pcDNA vector. Luciferase assays were carried out with Dual-Luciferase kit (Promega, Madison, WI, USA), and luciferase activity was normalized to transfection efficacy, using cotransfection of a Renilla expression vector.

TGR5 Transcription

Expression data for TGR5 (GPBAR1) in EBV-transformed lymphoblastoid cell lines from the HapMap samples was available from the GENEVAR project [37], and expression in the n = 210 non-related individuals were correlated to SNP genotypes, using linear regression in an in-house web-based tool SNPEXP v1.1 (http://app3.titan.uio.no/biotools/tool.php?app=snpexp).

Statistical Methods

In vitro experiments were performed independently at least four times. Results were expressed as means ± standard error of the mean, and analyzed using two-sided t-tests. P < 0.05 was considered statistically significant. SNP data were analyzed using Plink v1.06 [38] and Haploview v4.1 [39]. Allele frequencies were compared with chi-square tests or the Cochran-Mantel-Haenszel (CMH) test (across multiple panels). Heterogeneity of the odds ratios (ORs) of the panels was assessed with the Breslow-Day test. In order to control for the effect of rs11554825, logistic regressions were performed using Plink conditioning on rs11554825 with inclusion of study panel as a covariate. Linkage disequilibrium (LD) was calculated in healthy controls.

Results

Resequencing and Three-Dimensional Modeling of TGR5

Resequencing of the TGR5 gene in 267 Norwegian PSC patients and 274 healthy controls revealed a total of 29 SNPs (Table 2 and Figure S1). Twenty-two out of 29 were previously not described in any database (novel), and six of these 22 were nonsynonymous. Four nonsynonymous mutations were found in PSC patients only (W83R, A153V, V178M and S272G), one in both a PSC patient and three healthy controls (A217P), and one in...
Expression and Function of Mutated TGR5

In order to investigate the effect on receptor localization and expression, the nonsynonymous mutations were introduced into several different constructs and transfected into cell lines. Wild-type TGR5 as well as the W83R, A153V, V178M, A217P and S272G variants all localized to the plasma membrane irrespective of cell line (MDCK or HEK293) or construct (TGR5-YFP, FLAG-TGR5-YFP or TGR5) used, as shown in Figure 3A, Figure S4, Figure S5, Figure S6 and Figure S7. Of particular importance is that TGR5 expressed without tags (Figure S6 and Figure S7) was localized identically to tagged receptors, since tags may alter the localization or function of proteins. When introducing the stop codon (Q296X), the mutated protein was not detected by the TGR5 antibody, which is directed against the C-terminus. Also, when using YFP-tagged constructs, the Q296X mutation resulted in a non-detectable truncated protein without YFP. However, by using an anti-FLAG antibody, FLAG-Q296X-YFP could be detected in the endoplasmic reticulum (ER) as demonstrated by the co-localization with the endoplasmatic reticulum marker calnexin (Figure 3B/C).

Subsequently, the amount of protein produced and the proportion actually localized within the plasma membrane, was quantified using YFP-constructs and flow cytometry analysis in non-permeabilized and permeabilized cells. Protein expression of TGR5-W83R and TGR5-A217P was significantly reduced as compared with wild-type TGR5 (Figure 4A), even though transfection efficacy was similar for all constructs (Figure S8). In HEK293 cells 89% of wild-type TGR5 was located in the plasma membrane, which was similar for the W83R, A153V, V178M and A217P variants, while TGR5-S272G showed significantly reduced plasma membrane localization (80%, p = 0.025, Figure 4B).

TGR5 activity was analyzed using a cAMP-luciferase reporter gene assay following stimulation with TLC, which is the most potent endogenous agonist [36]. Forskolin increases cAMP independently of TGR5 and was used as positive control. Wild-type TGR5 exhibited high activity at 0.5 µM TLC and saturated at 2.5 µM (Figure 5A). W83R and V178M showed a significant decrease

Figure 3. Localization of TGR5 by confocal microscopy. In Panel A, polarized MDCK cells were transiently transfected with the different TGR5-YFP variants including wild-type (TGR5-WT-YFP). All variants except TGR5-Q296X-YFP reached the plasma membrane, however TGR5-A217P-YFP and TGR5-S272G-YFP were also present in some intracellular vesicles. In Panel B, MDCK cells were transiently transfected with FLAG-TGR5-YFP constructs (wild-type and the Q296X mutant). The FLAG-tag was made visible using an anti-FLAG-M2 antibody (in red) and the yellow coloring in the overlay demonstrates that the FLAG antibody completely binds to the FLAG-TGR5-YFP wild-type protein both in the plasma membrane as well as in intracellular vesicles (upper row). Introduction of the mutation Q296X leads to a premature stop codon and results in a truncated FLAG-Q296X-YFP protein as demonstrated by the absence of the YFP-fluorescence, but by using the anti-FLAG antibody the truncated protein could be detected (lower row). In Panel C, HEK293 cells were transiently transfected with the Q296X mutant of FLAG-TGR5-YFP (for the remaining variants, see Figure S5). The truncated protein, stained with the anti-FLAG antibody, was almost completely retained in the endoplasmatic reticulum, as demonstrated by the colocalization with the endoplasmatic reticulum marker calnexin. Nuclei were stained with Hoechst. Bars = 10 µm.

doi:10.1371/journal.pone.0012403.g003

Figure 4. Quantification of expression and localization of TGR5 variants. Panel A shows TGR5-YFP protein expression measured by flow cytometry. Mean fluorescence intensity per transfected cell was calculated, and expression of TGR5-WT-YFP (wild-type) was set to 1.0. Untransfected cells (Co) served as controls. The protein expression levels of the W83R (0.77±0.02, n = 6) and A217P (0.72±0.02, n = 6) variants were reduced. Results are shown as mean±standard error of the mean. ***Indicates significant difference (p<0.001) compared with wild-type. Panel B shows membrane localization of FLAG-TGR5-YFP variants as determined by flow cytometry. The N-terminal FLAG-tag is localized extracellularly and can be labeled with antibodies only when TGR5 is localized in the plasma membrane. The amount of receptor within the plasma membrane was determined by dividing the amount of FLAG-labeled TGR5 by the total amount of TGR5, as determined by YFP-fluorescence. In HEK293-cells 89±2% (n = 7) of wild-type was located in the plasma membrane, which was similar to W83R, A153V, V178M and A217P. The S272G variant showed significantly reduced plasma membrane localization compared with wild-type (80±3%, n = 7). Results are shown as mean±standard error of the mean. *Indicates significant difference (p<0.05) as compared with wild-type.

doi:10.1371/journal.pone.0012403.g004

a healthy control only (Q296X). Of non-coding variants, three common SNPs in strong LD were detected, of which rs11554825 was located in the untranslated TGR5 exon 1, while rs3731859 (r² = 0.99 with rs11554825) and rs13003334 (r² = 0.97 with rs11554825) were located in and near a reported transcript in the 5’ untranslated region (Figure 1).

TGR5 is conserved in mammals and other vertebrates. Since a molecular structure of TGR5 was not available, a structural model was generated by comparative modeling in order to predict the role of the nonsynonymous mutations (for details see Results S1). The model shows the seven transmembrane helices standard for G protein-coupled receptors (GPCRs) and a short intracellular C-terminal α-helix (Figure 2A). Residues affected by nonsynonymous mutations were distributed in all parts of the receptor. W83R and A153V were localized in extracellular loops, V178M and S272G in the transmembrane segments and A217P and Q296X in intracellular loops (Figure 2B). These substituted residues were in general conserved in mammals, except Ala153 not conserved in bovine and Ala217 not conserved in guinea-pig (Figure 2C, Figure S2 and Figure S3). Gln296 was not conserved, but Q296X stops the translation of several conserved C-terminal residues.
Figure 5. Activation of TGR5 variants by the bile acid taurolithocholic acid (TLC). HEK293 cells were cotransfected with TGR5 and a reporter gene containing five cAMP responsive elements in front of the luciferase gene. Luciferase activity served as a measure of the rise in intracellular cAMP following activation of TGR5. Forskolin (F, 10 μM) stimulated cAMP production independently of TGR5 and served as positive control. Results are expressed as mean±standard error of the mean. *Indicates significant difference (p<0.05) as compared with TGR5 wild-type (TGR5-WT). **p<0.01. ***p<0.001. In Panel A, activation of TGR5 wild-type (TGR5-WT) by TLC led to significant rises in luciferase activity already at a concentration of 0.1 μM (n = 14). Panel B and D show significantly reduced responses from TGR5-W83R (n = 4) and TGR5-V178M (n = 9) to 0.1, 0.5 and 2.5 μM TLC compared with TGR5-WT, while the responses to forskolin and 10 μM TLC were unaffected. The A153V variant did not affect receptor activity (Panel C, n = 12). The A217P (Panel E, n = 6) and Q296X (Panel G, n = 7) variants completely lost responsiveness to TLC. Panel F shows the S272G variant, which exhibited suppressed activation of luciferase by both forskolin and TLC at concentrations of 0.5, 2.5 and 10 μM (n = 11). doi:10.1371/journal.pone.0012403.g005
TGR5 in PSC

**A**

![Graph showing chromosome 2 position (Mb) and recombination rate (cM/Mb)]

- **UC GWAS**
- **PSC GWAS**
- **Recombination rate** (cM/Mb)
- **Region fine-mapped in Figure B below**

**B**

![Graph showing linkage disequilibrium (r² values)]

- **RUFY4**
- **IL8RB**
- **IL8RA**
- **ARPC2**
- **AAMP**
- **PNKD**
- **TGR5**
- **TMBIM1**
- **Meta-analysis PSC/UC**
- **PSC panel 1 subset**
- **UC panel 3 subset**
- **UC panel 4**
- **TGR5 SNP rs11554625**
- **Resequenced region**

**Linkage disequilibrium (r² values)**

- 0.90-1.0
- 0.85-0.89
- 0.80-0.79
- 0.75-0.79
- 0.70-0.69
- 0.65-0.69
- 0.60-0.69
- 0.55-0.69
- 0.50-0.69
- 0.45-0.69
- 0.40-0.69
- 0.35-0.69
- 0.30-0.69
- 0.25-0.69
- 0.20-0.69
- 0.15-0.69
- 0.10-0.69
- 0.05-0.69
- 0.00-0.69
Genetic Associations at Chromosome 2q35

In parallel with TGR5 sequencing, fine-mapping at chromosome 2q35 was performed in PSC and UC. Figure 6A shows overlapping and distinct peaks of statistically significant associations at chromosome 2q35 in SNP data from previous genome-wide association studies in PSC and UC [20,21]. Further fine-mapping in PSC and UC panels, including a joint PSC-UC meta-analysis of the fine-mapped panels, was subsequently performed in the peak region (Figure 6B). A high degree of LD was revealed, meaning that alleles at TGR5 and several neighboring loci occurred more frequently together than would have been expected by chance (Figure 6B). A recombination hot-spot separated the IL8RA and IL8RB genes from a LD block encompassing TGR5 and flanking genes, but further demarcation of a susceptibility variant at chromosome 2q35 was not possible.

Following up on the findings from the TGR5 sequencing, the only common exonic SNP in the gene was subsequently genotyped in all available study panels. In the combined analysis in PSC (1109 patients and 3593 healthy controls) and UC (2761 patients and 2096 healthy controls), rs11554825 was associated at a similar level [PSC OR = 1.15 (1.05–1.27), \( p_{\text{CMH}} = 0.0044 \) and UC OR = 1.19 (1.11–1.28), \( p_{\text{CMH}} = 5.6 \times 10^{-7} \)]. The rs11554825 and rs12612347 SNPs were in strong LD (\( r^2 = 0.73 \)), and logistic regression demonstrated that the effects were not independent. However, when controlling for the effect of rs11554825 (Figure 6B, highlighted in red) in the joint PSC-UC analysis of the fine-mapping panels, three SNPs in LD showed evidence of independent association (considering \( p < 0.05 \) as the threshold), with the lowest \( p \)-value at rs674271 (\( p_{\text{rs11554825}} = 0.0025 \), Results S1). These SNPs had minor allele frequencies of 0.04–0.05 (in the healthy controls) and were in LD with other low frequency SNPs throughout the locus (Figure 6B and Results S1). In conclusion, the original reported association at chromosome 2q35 may be caused by rs11554825, but several independent variants could have an effect at this locus.

The \( p \)-value for rs11554825 on TGR5 mRNA expression was investigated in a publically available dataset from lymphoblastoid cell-lines. Alleles at the PSC and UC associated rs11554825 were in almost perfect LD with alleles at the 5′ untranslated region (5′UTR) rs3731859 (\( r^2 = 0.99 \), Figure 1). There was a weak but significant correlation between expression of TGR5 and rs3731859 genotypes (\( r^2 \) (explained variance) = 0.048, \( p = 0.0015 \), Figure S9). The lowest expression was observed in individuals homozygous for allele G, which was linked to risk allele C at rs11554825.

Table 3. Minor allele frequencies and association analysis of TGR5 SNP rs11554825.

<table>
<thead>
<tr>
<th>Panel</th>
<th>n</th>
<th>Panel 2</th>
<th>n</th>
<th>Panel 3</th>
<th>n</th>
<th>Panel 4</th>
<th>OR (95% CI)</th>
<th>( p_{\text{CMH}} )</th>
</tr>
</thead>
<tbody>
<tr>
<td>Healthy controls</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>n*</td>
<td>666/422/298</td>
<td>1095/331/583</td>
<td>1832/356/1519</td>
<td>1104/NA/361</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Healthy controls</td>
<td>0.407</td>
<td>0.412</td>
<td>0.414</td>
<td>0.434</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PSC</td>
<td>0.459</td>
<td>0.440</td>
<td>0.432</td>
<td>NA</td>
<td></td>
<td></td>
<td>1.14 (1.03–1.26)</td>
<td>0.010</td>
</tr>
<tr>
<td>UC</td>
<td>0.471</td>
<td>0.429</td>
<td>0.463</td>
<td>0.475</td>
<td></td>
<td></td>
<td>1.19 (1.11–1.27)</td>
<td>8.5 \times 10^{-7}</td>
</tr>
</tbody>
</table>

*\( n \): number of healthy controls/PSC patients/UC patients.

*Breslow-Day test yielded no evidence for heterogeneity of odds ratio (\( p \)-values 0.52 and 0.40, respectively). CI, confidence interval; OR, odds ratio (compared with healthy controls); NA, not applicable; \( p_{\text{CMH}} \), \( p \)-value as calculated with Cochran-Mantel-Haenszel test across available panels; PSC, primary sclerosing cholangitis; UC, ulcerative colitis.
valuable insight into the structural biology of the receptor. The statistical associations detected for one exonic SNP in both PSC and UC emphasize the possibility that TGR5 may influence disease susceptibility in these conditions, but further studies are required to exclude a role for neighboring genes.

GPCRs are important mediators of physiological responses, as well as therapeutic targets [40]. It has proven very challenging to resolve experimentally the molecular structure of GPCRs [40]. The structure-function relationship and effects of mutations are therefore of great interest both for TGR5 and GPCRs in general. One example is the A217P mutation, which caused a complete loss of TGR5 activity as measured by the luciferase assay, pointing to a crucial role of the third intracellular loop for TGR5 function. In other GPCRs this loop has been found to be important for interaction with the G protein [41], and interestingly, it is a key target for a new class of GPCR specific agonists and antagonists named pepducins [42]. The residues Trp83 and Val178 are both conserved in mammals, and the mutations W83R and V178M led to significantly reduced TGR5 response to TLC concentrations (0.1–2.5 μM) close to the concentration known to induce half maximal activity of wild-type TGR5 (0.29 μM) [36]. This reduced activity corresponds to a right-shifted dose-response curve, implying either reduced affinity or efficacy of the agonist. For W83R this may be explained by the position of Trp83 in the first extracellular loop, suggesting that the mutation affects ligand binding. However, the accuracy of the receptor model in this part of the molecule was too low to allow detailed studies of possible mechanisms. The reduced activity of the V178M mutated protein could possibly be explained by the localization of Val178 in the fifth transmembrane helix, close to conserved residues involved in propagation of conformational changes from the ligand-binding pocket to the G-protein [43].

The S272G mutation abolished both responsiveness towards TLC (TGR5 dependent) and forskolin (TGR5 independent), suggesting altered interaction of TGR5 with downstream signaling targets. Ser272 is conserved in all vertebrates and positioned in the seventh transmembrane helix, likely to be important for transmitting conformational changes. One possibility is that S272G is an example of a constitutively active mutant, non-responsive to ligands, which simultaneously diminishes the response to forskolin by saturating adenylyl cyclase [44]. The A153V mutation appeared to be without functional consequences when using TLC as agonist, but it can not be excluded that mutation of this extracellular residue could affect the response to other endogenous agonists. Although minor changes in TGR5 expression and plasma membrane localization were noted for several mutations, the premature stop codon Q296X was the only mutation with a major impact. By deleting 35 G-terminal residues, it led to an almost complete retention of the receptor in the endoplasmic reticulum. This indicates that the cytoplasmic tail is required for normal surface expression, in line with observations made with the G protein-coupled angiotensin receptor AT1A [45].

In summary our results show that nonsynonymous mutations may critically affect targeting of TGR5 to the membrane, agonist binding, propagation of conformational changes through the membrane, or intracellular signaling.

The TGR5 common SNP was statistically associated with both PSC and UC in large European patient panels, but conclusive evidence defining TGR5 as a disease gene in these conditions could not be established. The main challenge was strong LD spanning the locus, which is a common obstacle to the conclusive identification of disease genes [46]. In addition there was statistical evidence for independently associated risk variants at 2q35, but the importance and nature of such variants can only be speculated based on the present data. Regarding TGR5, further experimental studies along with genetic mapping in other ethnicities will be needed to overcome the limitations in present data. The important notion that nonsynonymous mutations were observed in both PSC patients and healthy controls is not surprising, since only heterozygosity was observed, and genetically complex traits like PSC and UC are caused by an interplay of multiple genetic variants and environmental factors [47,48]. The mutations were too rare to explain the statistical associations, but yielded an opportunity to investigate the variable effects from naturally occurring genetic variation.

For common variants, the biological effects are often weak and difficult to elucidate, and the correlation between expression levels of TGR5 and rs11554825 genotypes was not strong, but still in line with recent findings in other diseases [49], and could therefore be speculated to contribute to the associations with PSC and UC. Furthermore, while the effect size was weak in statistical terms (OR), the association may still be important by suggesting an involvement of TGR5 related pathways in PSC and UC [50]. Further exploration of the implicated mechanisms of such an involvement may shed new light on the role of bile acids in intestinal and biliary inflammation, which could ultimately have therapeutic implications. This is particularly relevant for PSC, where no medical treatment has yet been shown to influence progression to liver cirrhosis and liver transplantation [51].

**Supporting Information**

**Materials and Methods S1** Supporting information about the subjects and the cloning and mutagenesis of human TGR5.

Found at: doi:10.1371/journal.pone.0012403.s001 (0.05 MB DOC)

**Results S1** Supporting results from the resequencing of TGR5, the sequence collection, the structure modeling and the genetic associations at chromosome 2q35.

Found at: doi:10.1371/journal.pone.0012403.s002 (0.09 MB DOC)

**Figure S1** Chromatograms from one heterozygote of each SNP detected through resequencing of TGR5.

Found at: doi:10.1371/journal.pone.0012403.s003 (1.14 MB DOC)

**Figure S2** Multiple sequence alignment of human TGR5 and orthologs (N-terminal half). Human TGR5 and orthologs from the primates Pan troglodytes (chimpanzee), Pongo pygmaeus (orangutan), Macaca mulatta (macaque), and Otolemur garnettii (bushbaby), other mammals such as Oryctolagus cuniculus (rabbit), Canis familiaris (dog), and Bos taurus (cow), the marsupial Monodelphis domestica (opossum), the lizard Anolis carolinensis, and the frog Xenopus tropicalis, and the fish Oryzias latipes (medaka), other mammals such as Oreochromis niloticus (nile tilapia), and the frog Xenopus laevis (X. laevis). The mutations were found in humans have been highlighted, and the Cys85-Cys155 disulfide bridge has been indicated (dashed line).

Found at: doi:10.1371/journal.pone.0012403.s004 (3.55 MB TIF)

**Figure S3** Multiple sequence alignment of TGR5 (C-terminal half) from the same species as in Figure S2. Residues found to be mutated in humans have been highlighted.

Found at: doi:10.1371/journal.pone.0012403.s005 (6.29 MB TIF)
**Figure S4** Localization of TGR5-YFP variants in HEK293 cells. HEK293 cells were transiently transfected with the different TGR5-YFP variants. An antibody against Na+/K+-ATPase was used to stain the plasma membrane (shown in red). Nuclei were stained with Hoechst (blue). A. Wildtype TGR5 (WT) was almost completely targeted to the plasma membrane. B. The mutant TGR5-W383R-YFP was also localized in the plasma membrane as demonstrated by the colocalization with the Na+/K+-ATPase resulting in a yellow coloring in the overlay picture. C. Introduction of A153V into TGR5-YFP did not affect plasma membrane localization. D. TGR5-V178M-YFP was also targeted to the plasma membrane as shown by the colocalization with the Na+/K+-ATPase fluorescence pattern. E. TGR5-A217P-YFP was also detected in the plasma membrane as demonstrated by the yellow coloring in the superimposed image. F. TGR5-S272G-YFP was both localized in the plasma membrane but also in some intracellular vesicles. Bars = 10 μm. Found at: doi:10.1371/journal.pone.0012403.s008 (4.21 MB TIF)

**Figure S5** Localization of FLAG-TGR5-YFP in HEK293 cells. HEK293 cells were transiently transfected with the different FLAG-TGR5-YFP constructs. The FLAG-tag was made visible using an anti-FLAG-M2 antibody (in red). The yellow coloring in the overlay images demonstrate that the FLAG antibody completely binds to the FLAG-TGR5-YFP proteins both in the plasma membrane as well as in intracellular vesicles (A–D). Nuclei were stained with Hoechst. Bars = 10 μm. Found at: doi:10.1371/journal.pone.0012403.s006 (5.32 MB TIF)

**Figure S6** Localization of TGR5 in pcDNA in HEK293 cells. HEK293 cells were transiently transfected with the different TGR5 variants (without tags) and stained for TGR5 using the anti-TGR5 (M39) antibody (shown in red). An antibody against Na+/K+-ATPase was used as a marker for the plasma membrane (shown in green). Nuclei were stained with Hoechst (blue). Wildtype TGR5 (TGR5-WT) was almost completely targeted to the plasma membrane. All TGR5-variants were also localized in the plasma membrane of HEK293 cells as demonstrated by the colocalization with the fluorescence from the Na+/K+-ATPase antibody. Found at: doi:10.1371/journal.pone.0012403.s007 (4.35 MB TIF)

**Figure S7** Localization of TGR5 in pcDNA in MDCK cells. TGR5 variants were transfected into polarized MDCK cells. TGR5 and TGR5 mutants were all detected in the plasma membrane using the anti-TGR5 antibody (M39 in red). Bars = 10 μm. Found at: doi:10.1371/journal.pone.0012403.s008 (4.21 MB TIF)

**Table S1** Details of the nine primer pairs used in TGR5 resequencing (M13-primer-sequence underlined). Found at: doi:10.1371/journal.pone.0012403.s012 (0.04 MB DOC)

**Note S1** List of members in the IBSEN study group. Found at: doi:10.1371/journal.pone.0012403.s013 (0.03 MB DOC)

**Acknowledgments**

The authors wish to thank all patients and healthy controls for their participation. We thank Hege Dahlén Sollid, Bente Woldseth, Kristian Holm and Stefanie Winandy for expert technical assistance and Marte K. Viken for helpful discussions. The Norwegian Bone Marrow Donor Registry (NORDONOR) at Oslo University Hospital Rikshospitalet, and the Popgen biobank are acknowledged for contributing healthy control populations. We acknowledge the use of DNA from the 1958 British Birth Cohort collection (R. Jones, S. Ring, W. McArell and M. Pembrey).

**Author Contributions**

Conceived and designed the experiments: JRH VK DH AF THK. Performed the experiments: JRH VK JKL LS EE TB AF THK. Analyzed the data: JRH VK JKL AE EM TM THK. Contributed reagents/materials/analysis tools: KMB CS AB TW DG CR LH CMO RKW MS AT HR AS CYP CW MHV IBSEN study group PCFS SV CGM BAL UB MPM SS ES DH. Wrote the paper: JRH VK JKL THK. Revised the manuscript for critical content and approved the final version: JRH VK JKL AE EM TM THK. Performed the experiments: JRH VK JKL LS EE AE EM KMB TM TB CS AB TW DG CR LH CMO RKW MS AT HR AS CYP CW MHV IBSEN study group PCFS SV CGM BAL UB MPM SS ES DH AF THK.  

References

15. Bergquist A, Montgomery SM, Rahmanay S, Olson R, Danielson A, et al. (2008) Increased risk of primary sclerosing cholangitis and ulcerative colitis in...


